uniQure N.V. — fact timeline

uniQure N.V.: Amended articles of association to reflect Dutch large company regime, increase authorized share capital, and add federal forum selection provision (effective 2026-06-10).

“On June 10, 2026, at the Annual Meeting, the shareholders of the Company approved proposed amendments to the Company’s articles of association (the “ Articles of Association ”) to (i) reflect the Dutch large company regime, (ii) increase the Company's authorized share capital, and (iii) provide that the federal district courts of the United States will serve as the exclusive forum for the adjudication of certain legal disputes. Subsequent to such approval, the Company filed, on June 15, 2026, with the Dutch Trade Register at the Netherlands Chamber of Commerce a deed of amendment (the “ Deed of Amendment ”), giving effect to the exclusive forum provision and to the authorized ordinary share increase.”

uniQure N.V. shareholders approved Resolution to adopt the amendment to the Company’s Articles of Association to include a federal forum selection provision at the 2026-06-10 meeting.

“Proposal 15 - Resolution to adopt the amendment to the Company’s Articles of Association to include a federal forum selection provision. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 33,960,143 3,880,065 69,211 6,613,632”

uniQure N.V. shareholders approved Resolution to adopt the amendment to the Company’s Articles of Association to increase the authorized share capital and number of ordinary shares at the 2026-06-10 meeting.

“Proposal 14 - Resolution to adopt the amendment to the Company’s Articles of Association to increase the authorized share capital and number of ordinary shares. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 37,616,838 265,504 27,077 6,613,632”

uniQure N.V. shareholders approved Resolution to adopt the amendment to the Company’s Articles of Association to reflect Dutch large company regime at the 2026-06-10 meeting.

“Proposal 13 - Resolution to adopt the amendment to the Company’s Articles of Association to reflect Dutch large company regime. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 28,197,514 9,657,289 54,616 6,613,632”

uniQure N.V. shareholders approved Resolution to adopt the Plan Amendment and authorize the Board to issue ordinary shares and grant rights to subscribe for ordinary shares pursuant to the 2014 Plan (as amended by the Plan Amendment) at the 2026-06-10 meeting.

“Proposal 12 - Resolution to adopt the Plan Amendment and authorize the Board to issue ordinary shares and grant rights to subscribe for ordinary shares pursuant to the 2014 Plan (as amended by the Plan Amendment). This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 37,461,945 389,128 58,346 6,613,632”

uniQure N.V. shareholders approved Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company at the 2026-06-10 meeting.

“Proposal 11 - Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company. The results of the advisory vote are set forth below. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 37,197,949 47,246 628,681 35,543 6,613,632”

uniQure N.V. shareholders approved Approval, on an advisory basis, the compensation of the named executive officers of the Company at the 2026-06-10 meeting.

“Proposal 10 - Approval, on an advisory basis, the compensation of the named executive officers of the Company. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 37,422,626 414,084 72,709 6,613,632”

uniQure N.V. shareholders approved Appointment KPMG Accountants N.V. as external auditors of the Company for the fiscal year 2026 at the 2026-06-10 meeting.

“Proposal 9 - Appointment KPMG Accountants N.V. as external auditors of the Company for the fiscal year 2026. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 44,419,027 82,473 21,551 0”

uniQure N.V. shareholders approved Reappointment of Leonard Post as non-executive director at the 2026-06-10 meeting.

“Proposal 5 - Reappointment of Leonard Post as non-executive director. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 37,326,031 550,517 32,871 6,613,632”

uniQure N.V. shareholders approved Reappointment of Jack Kaye as non-executive director at the 2026-06-10 meeting.

“Proposal 4 - Reappointment of Jack Kaye as non-executive director. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 37,256,535 619,247 33,637 6,613,632”

uniQure N.V. shareholders approved Reappointment of Madhavan Balachandran as non-executive director at the 2026-06-10 meeting.

“Proposal 3 - Reappointment of Madhavan Balachandran as non-executive director. This proposal was approved as set forth below. For Against Abstain Broker Non-Votes 37,342,223 533,759 33,437 6,613,632”

uniQure N.V. reported financial results for first quarter of 2026.

“uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.”

uniQure N.V. incurred term loan of maximum aggregate amount of $175 million with Hercules Capital, Inc. at greater of (i) 9.45% and (ii) the sum of the prime rate and 2.45% maturing October 1, 2030.

“On September 22, 2025 (the “ Closing Date ”), uniQure N.V. (the “ Company ”) and certain of its affiliates entered into Amendment No. 3 to the Third Amended and Restated Loan and Security Agreement (the “ Amendment ”) with Hercules Capital, Inc. (“ Hercules ”), which amended certain terms of the Third Amended and Restated Loan and Security Agreement, dated December 15, 2021, by and among the Company, certain subsidiaries of the Company, and Hercules, as amended by that certain Amendment No. 1 to Third Amended and Restated Loan and Security Agreement, dated as of May 12, 2023 and Consent and Amendment No. 2 to Third Amended and Restated Loan and Security Agreement, dated as of June 28, 2024 (the “ Existing Loan Agreement ,” and the Existing Loan Agreement as amended by the Amendment, the “ Loan Agreement ”). Pursuant to the Amendment, Hercules agreed to make additional term loans in the maximum aggregate amount of $175 million (the “ 2025 Term Loan ”) to refinance the existing term loan”

uniQure N.V. completed a disposition involving Genezen MA, Inc. and Genezen Holdings, Inc. for shares of newly issued Series C preferred stock of Genezen Holdings valued at $12.5 million...and a $12.5 million convertible promissory note (closed 2024-07-22).

“(the “ Lexington Transaction ”). At the closing of the Lexington Transaction, uniQure received (i) shares of newly issued Series C preferred stock of Genezen Holdings valued at $12.5 million, which are convertible into Genezen Holdings common stock and accrue an 8% per annum cumulative dividend, and (ii) a $12.5 million convertible promissory note from Genezen”

Pierre Caloz was terminated as Chief Operating Officer at uniQure N.V..

“In connection with the closing of the Lexington Transaction, on July 22, 2024, the Company notified Pierre Caloz, the Company’s Chief Operating Officer, that his employment was being terminated consistent with the terms of the employment agreement by and between uniQure biopharma B.V. and Mr. Caloz, dated May 17, 2021.”

uniQure N.V. reported the quarter ended March 31, 2024 results: revenue $8.5 million.

“Revenue for the three months ended March 31, 2024 was $8.5 million, compared to $5.3 million in the same period in 2023.”

Paula Soteropoulos departed as Non-executive director at uniQure N.V..

“On April 9, 2024, Paula Soteropoulos notified the board of directors (the “ Board ”) of uniQure N.V. (the “ Company ”) that she will not stand for re-election as a non-executive director when her current term expires at Company’s 2024 annual meeting of shareholders.”

uniQure N.V. reported fourth quarter and full year 2023 results: revenue $15.8 million.

“Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2027. Revenues: Revenue for the year ended December 31, 2023 was $15.8 million, compared to $106.5 million in the same period in 2022. Revenues in 2022 included $100.0 million of license revenue related to the U.S. first sale milestone payment of HEMGENIX ®”

uniQure N.V. shareholders approved Increase in number of shares available under the 2014 Plan Restatement at the 2023-11-15 meeting.

“Voting Proposal 2 – If Voting Proposal No. 1 is adopted, resolution to approve an increase in the number of shares available under the 2014 Plan Restatement and authorization of the Board as the competent body to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares pursuant to the 2014 Plan. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 23,907,957 1,855,973 23,750 0”

uniQure N.V. shareholders approved Amendment and restatement of the Company’s 2014 Share Incentive Plan at the 2023-11-15 meeting.

“Voting Proposal 1 - Resolution to approve the amendment and restatement of the Company’s 2014 Share Incentive Plan. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 23,912,867 1,853,438 21,375 0”

uniQure N.V. reported financial results for the quarter ended September 30, 2023.

“On November 7, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023”

uniQure N.V. announced a restructuring with charges of approximately $2.3 million affecting global workforce and research operations (approximately 28% of the Company’s global workforce).

“The Plan includes the discontinuation of more than half of the Company’s research and technology projects, the elimination of approximately 28% of the Company’s global workforce and the closure of a research lab in Lexington, MA. The Company estimates that it will incur charges of approximately $2.3 million in connection with the Plan, consisting primarily of cash expenditures related to employee severance costs.”

Richard Porter changed role as Chief Business and Scientific Officer at uniQure N.V..

“the Board of Directors of the Company have designated Richard Porter, the Company’s current Chief Business Officer, to serve as the Company’s Chief Business and Scientific Officer, effective as of October 5, 2023.”

Ricardo Dolmetsch was terminated as Chief Scientific Officer at uniQure N.V..

“On October 5, 2023, the Company announced that, effective October 4, 2023 (the “Effective Date”), Ricardo Dolmetsch terminated his employment with the Company as its Chief Scientific Officer for Good Reason”

uniQure N.V. reported financial results for the quarter ended June 30, 2023.

“On August 1, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023, and highlighting company progress.”

uniQure N.V. shareholders rejected Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan at the 2023-06-13 meeting.

“Voting Proposal 12 - Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan. This proposal was not approved as set forth below: For Against Abstain Broker Non-Votes 12,728,636 17,056,763 12,753 5,157,842”

uniQure N.V. shareholders approved Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company at the 2023-06-13 meeting.

“Voting Proposal 11 - Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 29,174,332 610,091 13,729 5,157,842”

uniQure N.V. shareholders approved Resolution to appoint KPMG Accountants N.V. as external auditors of the Company for the financial year 2023 at the 2023-06-13 meeting.

“Voting Proposal 10 - Resolution to appoint KPMG Accountants N.V. as external auditors of the Company for the financial year 2023. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 34,882,126 11,413 62,455 0”

uniQure N.V. shareholders approved Resolution to reauthorize the Board to repurchase Ordinary Shares at the 2023-06-13 meeting.

“Voting Proposal 9 - Resolution to reauthorize the Board to repurchase Ordinary Shares This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 34,809,932 67,984 78,078 0”

uniQure N.V. shareholders rejected Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares and granting of rights to subscribe for Ordinary Shares at the 2023-06-13 meeting.

“Voting Proposal 8 - Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares and granting of rights to subscribe for Ordinary Shares. This proposal was not approved as set forth below: For Against Abstain Broker Non-Votes 16,623,482 18,246,948 85,564 0”

uniQure N.V. shareholders rejected Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares at the 2023-06-13 meeting.

“Voting Proposal 7 - Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares. This proposal was not approved as set forth below: For Against Abstain Broker Non-Votes 16,651,973 18,230,724 73,297 0”

uniQure N.V. shareholders approved Reappointment of directors at the 2023-06-13 meeting.

“Voting Proposal 3 - Reappointment of Madhavan Balachandran as non-executive director. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 29,556,652 224,245 17,255 5,157,842 Voting Proposal 4 - Reappointment of Jack Kaye as non-executive director. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 29,658,725 122,107 17,320 5,157,842 Voting Proposal 5 - Reappointment of Leonard Post as non-executive director This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 29,725,336 55,893 16,923 5,157,842 Voting Proposal 6 - Reappointment of Jeremy Springhorn as non-executive director. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 28,032,354 1,749,356 16,442 5,157,842”

uniQure N.V. shareholders approved Resolution to discharge liability of the members of the Board of Directors (the “Board”) at the 2023-06-13 meeting.

“Voting Proposal 2 - Resolution to discharge liability of the members of the Board of Directors (the “Board”). This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 29,690,330 53,374 54,448 5,157,842”

uniQure N.V. shareholders approved Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results at the 2023-06-13 meeting.

“Voting Proposal 1 - Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results. This proposal was approved as set forth below: For Against Abstain Broker Non-Votes 34,885,068 13,546 57,380 0”

uniQure N.V. amended credit facility with Hercules Capital, Inc. maturing January 5, 2027.

“Additionally, the maturity date and the interest-only period of the Loan Agreement was extended to January 5, 2027.”

uniQure N.V. entered an off-balance-sheet arrangement for debt of $375 million with HemB SPV, L.P. maturing June 30, 2032.

“ith HemB SPV, L.P. (“Purchaser”) for the sale of a portion of the royalty rights due to the Company from CSL Behring LLC”

uniQure N.V. amended Amendment No. 1 to Third Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. valued at Extension of maturity date and interest-only period to January 5, 2027, and $1.25 million fee payabl (effective 2023-05-12).

“In connection with the execution of the Purchase Agreement, the Company entered into Amendment No. 1 (the “Amendment”) to the Third Amended and Restated Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) in its capacity as administrative agent and collateral agent for itself and the other financial institutions or entities party thereto as lenders (the “Lenders”).”

uniQure N.V. entered into Royalty Purchase Agreement with HemB SPV, L.P. valued at Upfront cash payment of $375 million, plus potential $25 million milestone payment (effective 2023-05-12).

“On May 12, 2023, uniQure biopharma BV, a wholly-owned subsidiary of uniQure N.V., (the “Company”) entered into a royalty purchase agreement (the “Purchase Agreement”) with HemB SPV, L.P. (“Purchaser”) for the sale of a portion of the royalty rights due to the Company from CSL Behring LLC (“CSL Behring”) under the commercialization and license agreement between the Company and CSL Behring dated as of June 24, 2020 (the “Commercialization and License Agreement”), from the net sales of HEMGENIX® (the “Product”).”

uniQure N.V. reported the first quarter of 2023 results: revenue $5.3 million.

“Revenue for the three months ended March 31, 2023 was $5.3 million, compared to $1.8 million in the same period in 2022.”

Alex Kuta retired as Chief Regulatory Officer at uniQure N.V..

“Alex Kuta, Chief Regulatory Officer of uniQure N.V. (the “Company”), has retired from the Company and its affiliates in all capacities, effective March 31, 2023”

uniQure N.V. reported financial results for the full year ended December 31, 2022.

“On February 27, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2022 and highlighting company progress.”

uniQure N.V. terminated BMS CLA with Bristol-Myers Squibb (effective 2023-02-21).

“On November 21, 2022, BMS provided, and the Company received, a notice that the BMS CLA, as amended, will terminate effective February 21, 2023 (the “Termination Notice”).”

uniQure N.V. reported financial results for the quarter ended September 30, 2022.

“On November 2, 2022, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and highlighting company progress.”